{"id":14685,"date":"2021-12-08T19:43:07","date_gmt":"2021-12-08T14:13:07","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=14685"},"modified":"2021-12-17T10:19:07","modified_gmt":"2021-12-17T04:49:07","slug":"osteoporosis-emerging-drugs","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs","title":{"rendered":"What All You Need to Know About Evolving Osteoporosis Therapeutic Landscape?"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d0562ac587a\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d0562ac587a\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs\/#Osteoporosis_Treatment\" >Osteoporosis Treatment&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs\/#Various_Emerging_Novel_and_Effective_Drugs_in_Osteoporosis\" >Various Emerging, Novel and Effective Drugs in Osteoporosis&nbsp;<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs\/#TVB-009_Teva_Pharmaceuticals\" >TVB-009 (Teva Pharmaceuticals)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs\/#NaQuinate_Haoma_Medica\" >NaQuinate (Haoma Medica)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs\/#SHR-1222_Jiangsu_HengRui_Medicine\" >SHR-1222 (Jiangsu HengRui Medicine)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs\/#HS-20090-2_Shanghai_Hansoh_Biomedical\" >HS-20090-2 (Shanghai Hansoh Biomedical)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs\/#Oral_PTH_Analogs_Enteris_Biopharma\" >Oral PTH Analogs (Enteris Biopharma)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs\/#EB613_Entera_Bio\" >EB613 (Entera Bio)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs\/#QL1206_Qilu_Pharmaceutical\" >QL1206 (Qilu Pharmaceutical)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs\/#CT-P41_Celltrion\" >CT-P41 (Celltrion)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs\/#What_Lies_in_the_Future_of_Osteoporosis\" >What Lies in the Future of Osteoporosis<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs\/#Frequently_Asked_Questions\" >Frequently Asked Questions<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n\n<p>Osteoporosis can be characterized by a decrease in the density of bone, resulting in fragile bones which can decrease its strength. Osteoporosis leads to an extent of abnormally porous bones that are observed to be very compressible, just like a sponge. This skeleton disorder cripples the bones and consequently result in frequent fractures (breaks) in the bones. Osteoporosis can be present without any symptoms for many years because Osteoporosis symptoms aren\u2019t caused until the bone breaks (fractures).<\/p>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/blog\/osteoporosis-symptoms-risk-factors-diagnosis-and-treatment-options\">Osteoporosis risk factors<\/a> include genetics,&nbsp; lack of calcium,&nbsp; lack of exercise, and vitamin D, personal history of fracture as an adult,&nbsp; excessive alcohol consumption, cigarette smoking, low body weight, history of rheumatoid arthritis, and family history of osteoporosis. Also, long-term usage of corticosteroids (such as prednisone, prednisolone, and cortisone) can be a sign of the disease. X-rays (dual-energy X-ray absorptiometry scan -DXA\/DEXA) is considered to be the standard <a href=\"https:\/\/www.delveinsight.com\/blog\/osteoporosis-symptoms-risk-factors-diagnosis-and-treatment-options\">Osteoporosis diagnosis tool<\/a>. This test typically measures the bone density in the hip, forearm, and spine.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/08190835\/Osteoporosis-Symptoms-01-01-01.jpg\" alt=\"symptoms-associated-with-osteoporosis\" class=\"wp-image-14701\" width=\"675\" height=\"306\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/08190835\/Osteoporosis-Symptoms-01-01-01.jpg 675w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/08190835\/Osteoporosis-Symptoms-01-01-01-300x136.jpg 300w\" sizes=\"(max-width: 675px) 100vw, 675px\" \/><figcaption><strong>Osteoporosis<\/strong> <strong>Associated<\/strong> <strong>Symptoms<\/strong><\/figcaption><\/figure>\n\n\n\n<p>As per DelveInsight analysis, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/osteoporosis-epidemiology-forecast\">total diagnosed prevalent population of Osteoporosis<\/a> in the 7MM&nbsp; was found to be <strong>28,097,783<\/strong> cases in <strong>2017<\/strong>. While the total diagnosed prevalent population of Osteoporosis in the United States was found to be <strong>6,380,754 <\/strong>cases in 2017, which is expected to increase by 2030.<\/p>\n\n\n\n<p>DelveInsight estimates that the <a href=\"https:\/\/www.delveinsight.com\/report-store\/osteoporosis-market\">global Osteoporosis market<\/a> accounted for <strong>USD 7,657 million<\/strong> in 2018, &nbsp;is anticipated to change at a<strong> CAGR of 3.9% <\/strong>by 2026. Many key pharmaceuticals are proactively working to develop Osteoporosis therapies including companies like <strong>Amgen Inc.<\/strong>,<strong> Novartis AG, Eli Lilly and Company, Pfizer Inc., Radius Health, Teva Pharmaceuticals, Jiangsu HengRui Medicine,&nbsp; Haoma Medica, Enteris Biopharma, Entera Bio, Qilu Pharmaceutical, Celltrion,<\/strong> and several others.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" width=\"675\" height=\"162\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/09131816\/Osteoporosis-Market-Outlook-Epidemiology-Insights-01-01.jpg\" alt=\"Market-insights-osteoporosis\" class=\"wp-image-14724\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/09131816\/Osteoporosis-Market-Outlook-Epidemiology-Insights-01-01.jpg 675w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/09131816\/Osteoporosis-Market-Outlook-Epidemiology-Insights-01-01-300x72.jpg 300w\" sizes=\"(max-width: 675px) 100vw, 675px\" \/><figcaption><strong>Market Insights<\/strong><\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Osteoporosis_Treatment\"><\/span><strong>Osteoporosis Treatment&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The goal of the <a href=\"https:\/\/www.delveinsight.com\/blog\/new-osteoporosis-drug-promises-to-rebuild-bone\">treatment for Osteoporosis<\/a> is mainly prevention of bone fractures by reducing bone loss or, preferably, by increasing bone density and strength. Even though early detection, as well as a timely treatment, can substantially result in a decrease in the risk of future fractures, none of the available treatments for Osteoporosis can be considered a complete cure.<\/p>\n\n\n\n<p>The following mentioned are a few of the Osteoporosis prevention and treatment measures for optimal health of the bone.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Lifestyle changes, including quitting cigarette smoking, curtailing excessive alcohol intake, exercising regularly, and consuming a balanced diet with adequate calcium and vitamin D.<\/li><li>Osteoporosis medications that stop bone loss and increase bone strength, such as alendronate (Fosamax),&nbsp; raloxifene (Evista), risedronate (Actonel), ibandronate (Boniva), calcitonin (Calcimar), zoledronate (Reclast), and denosumab (Prolia). Medications that increase bone formation such as teriparatide (Forteo).<\/li><li>Exercise has a wide variety of beneficial health effects. However, exercise does not bring about substantial increases in bone density. Osteoporosis exercises usually help in decreasing the risk of falls.<\/li><\/ul>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/08191012\/Various-Stages-of-Osteoporosis-2.jpg\" alt=\"osteoporosis-stages\" class=\"wp-image-14702\" width=\"633\" height=\"372\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/08191012\/Various-Stages-of-Osteoporosis-2.jpg 633w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/08191012\/Various-Stages-of-Osteoporosis-2-300x176.jpg 300w\" sizes=\"(max-width: 633px) 100vw, 633px\" \/><figcaption><strong> Stages<\/strong><\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-various-emerging-novel-and-effective-drugs-in-osteoporosis\"><span class=\"ez-toc-section\" id=\"Various_Emerging_Novel_and_Effective_Drugs_in_Osteoporosis\"><\/span><strong>Various Emerging, Novel and Effective Drugs in Osteoporosis&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The most effective <a href=\"https:\/\/www.delveinsight.com\/blog\/fda-approves-bonsity-for-osteoporosis\">FDA-approved Osteoporosis medication<\/a> includes a class of antiresorptive agents. They assist in decreasing the removal of calcium from the bones. The antiresorptive class of drugs aims at ensuring adequate bone remodelling, it provides reparation of microdamage of bone and also increases the overall bone strength. They inhibit the resorption of bone resulting in favour of bone rebuilding and increasing bone density. Hormone replacement therapy (HRT) is one of the best examples of an antiresorptive agent. Others include alendronate (Fosamax), raloxifene (Evista), risedronate (Actonel), ibandronate (Boniva), zoledronate (Reclast), calcitonin (Calcimar), and denosumab (Prolia).<\/p>\n\n\n\n<p>Below mentioned are some of the most anticipated <a href=\"https:\/\/www.delveinsight.com\/blog\/%ef%bb%bfemerging-drugs-bring-a-positive-shift-in-global-osteoporosis-market\">Osteoporosis drugs<\/a> to be launched in the upcoming years &#8211;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-tvb-009-teva-pharmaceuticals\"><span class=\"ez-toc-section\" id=\"TVB-009_Teva_Pharmaceuticals\"><\/span><strong>TVB-009 (Teva Pharmaceuticals)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Teva Pharmaceuticals<\/strong> in March 2021, initiated \u201cA Randomized, Double-Blind, Multinational,Multicenter Study to Compare Efficacy, Safety, and Immunogenicity of <strong>TVB-009<\/strong> and Denosumab (Prolia\u00ae) in postmenopausal women with Osteoporosis\u201d. TVB-009 is an inhibitor of the RANK ligand. It is a biosimilar of Denosumab. It is currently in the Phase III stage of the development <a href=\"https:\/\/www.delveinsight.com\/report-store\/osteoporosis-pipeline-insight\">pipeline for Osteoporosis<\/a>. The trial is currently active with 326 enrolled participants and is estimated to get completed by December 2023.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"NaQuinate_Haoma_Medica\"><\/span><strong>NaQuinate (Haoma Medica)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>NaQuinate <\/strong>is being developed by <strong>Haoma Medica<\/strong>, which is considered a novel therapeutic, the drug works in both Osteoporosis and Osteopenia, which is a compound that has a new mechanism of action compared with existing treatments and is designed for low-dose oral administration. The company has completed its Phase I first-in-human (FIH) clinical study in healthy subjects and Phase Ib study in healthy postmenopausal women has been initiated.&nbsp;Haoma Medica initiated the Phase II program for Osteoporosis later in 2020.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"SHR-1222_Jiangsu_HengRui_Medicine\"><\/span><strong>SHR-1222 (Jiangsu HengRui Medicine)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Jiangsu HengRui Medicine <\/strong>is running a phase I trial of <strong>SHR-1222 <\/strong>in postmenopausal Osteoporosis patients in China. SHR-1222 is a humanized monoclonal antibody targeting sclerostin and has the potential to promote bone formation and reduce bone resorption. The primary objective of this study is to investigate the safety and tolerability of a range of subcutaneous SHR-1222 in postmenopausal women with Osteoporosis.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-hs-20090-2-shanghai-hansoh-biomedical\"><span class=\"ez-toc-section\" id=\"HS-20090-2_Shanghai_Hansoh_Biomedical\"><\/span><strong>HS-20090-2 (Shanghai Hansoh Biomedical)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p id=\"h-\"><strong>Shanghai Hansoh Biomedical <\/strong>initiated a Phase I, single-centre, randomized, single-blind, and parallel-group clinical trial study to compare the pharmacokinetics, safety, and immunogenicity of <strong>HS-20090-2<\/strong> and Prolia\u00ae in healthy adults. The primary objective of this study is to assess the pharmacokinetic similarity of single subcutaneously injection of HS-20090-2 or Prolia\u00ae in healthy volunteers whereas the secondary objectives are to assess the clinical safety and immunogenicity. The study is currently in a recruiting stage with research revolving around postmenopausal women with Osteoporosis. The first clinical trials were started in June 2021 and volunteers recruited are aged between 18-50 years.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/08190638\/Various-Emerging-Therapies-in-Osteoporosis-and-Companies-Developing-Them-1.jpg\" alt=\"pharma-players-in-osteoporosis\" class=\"wp-image-14700\" width=\"491\" height=\"277\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/08190638\/Various-Emerging-Therapies-in-Osteoporosis-and-Companies-Developing-Them-1.jpg 491w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/08190638\/Various-Emerging-Therapies-in-Osteoporosis-and-Companies-Developing-Them-1-300x169.jpg 300w\" sizes=\"(max-width: 491px) 100vw, 491px\" \/><figcaption><strong>Key Pharma Players Proactively Working in the Osteoporosis Domain<\/strong><\/figcaption><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Oral_PTH_Analogs_Enteris_Biopharma\"><\/span><strong>Oral PTH Analogs (Enteris Biopharma)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Enteris BioPharma\u2019s<\/strong> oral peptide and small molecule delivery technology has been applied to a range of molecules across multiple therapeutic areas. The technology is the subject of several active externally sponsored pre-clinical and clinical development programs, the most advanced of which include <strong>R-Pharm\u2019s TBRIA, oral calcitonin <\/strong>for postmenopausal women with Osteoporosis.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-eb613-entera-bio\"><span class=\"ez-toc-section\" id=\"EB613_Entera_Bio\"><\/span><strong>EB613 (Entera Bio)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The Phase 2 clinical trial of <strong>EB613 <\/strong>by<strong> Entera Bio<\/strong> is an oral formulation of human parathyroid hormone (PTH) (1-34), for the <a href=\"https:\/\/www.delveinsight.com\/blog\/new-osteoporosis-drug-promises-to-rebuild-bone\">treatment of Osteoporosis<\/a>. It met the primary and key secondary endpoints, positioning it to be the first oral bone building (anabolic) product to treat Osteoporosis patients. This Phase 2 Dose-Ranging study in Osteoporosis showed clinically significant changes in increases in BMD at the spine, femoral neck, and total hip. These BMD changes were associated with an increase in P1NP and a decrease in the serum CTX biomarker. A difference between the increase in P1NP, a marker of bone formation and the change in CTX, a marker of bone resorption, usually indicates an increase in bone mass, and is sometimes referred to as an \u201canabolic window.\u201d<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-ql1206-qilu-pharmaceutical\"><span class=\"ez-toc-section\" id=\"QL1206_Qilu_Pharmaceutical\"><\/span><strong>QL1206 (Qilu Pharmaceutical)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Qilu Pharmaceutical <\/strong>initiated a randomized, double-blind, two-group parallel, placebo-controlled clinical Phase III trial to compare the efficacy and safety of <strong>QL1206 <\/strong>and placebo in postmenopausal women with Osteoporosis at high risk of fracture. The primary objective is to evaluate the effect of QL1206 treatment compared with placebo in Chinese postmenopausal women with Osteoporosis at high risk of fracture. The secondary objective is to evaluate the clinical safety, immunogenicity, and pharmacokinetics (PK) characteristics of QL1206 in women with osteoporosis at high risk of postmenopausal fracture. The estimated primary completion was done by August 31, 2021, whereas secondary completion is supposed to be completed by December 2021. Volunteers in this study are aged between 50 to 85 Years (Adult, Older Adult).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-ct-p41-celltrion\"><span class=\"ez-toc-section\" id=\"CT-P41_Celltrion\"><\/span><strong>CT-P41 (Celltrion)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Celltrion <\/strong>commenced a double-blind, randomized, active-controlled, Phase 3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of<strong> CT-P41 <\/strong>and US-licensed Prolia in <a href=\"https:\/\/www.delveinsight.com\/report-store\/post-menopausal-osteoporosis-market\">Postmenopausal Women with Osteoporosis<\/a>. All patients will also receive daily supplementation containing at least 1,000 mg of elemental calcium and at least 400 IU vitamin D from randomization to EOS visit and the data will be collected via the patient&#8217;s diary. The study is currently in the active, not recruiting stage and the patients who participated are around 50 to 80 years of age.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-lies-in-the-future-of-osteoporosis\"><span class=\"ez-toc-section\" id=\"What_Lies_in_the_Future_of_Osteoporosis\"><\/span><strong>What Lies in the Future of Osteoporosis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The current market scenario of Osteoporosis is heavily dominated by biosimilars and generics, which are quite promising and potential for the treatment of osteoporosis. However, the upcoming pipeline for Osteoporosis holds many significant therapies that are developed by key pharma players. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/osteoporosis-pipeline-insight\" target=\"_blank\" rel=\"noreferrer noopener\">current pipeline of Osteoporosis<\/a> marks a significant unmet need due to the availability of only a few products. There is an immediate requirement of developing new and efficient drugs in the Osteoporosis pipeline so that the emerging drugs market of Osteoporosis can flourish.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/osteoporosis-pipeline-insight\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" width=\"1024\" height=\"256\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/09131617\/Pipeline-Assessment-Around-Clients-Area-of-Interest-1-1024x256.jpg\" alt=\"osteoporosis-pipeline-assessment\" class=\"wp-image-14722\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/09131617\/Pipeline-Assessment-Around-Clients-Area-of-Interest-1-1024x256.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/09131617\/Pipeline-Assessment-Around-Clients-Area-of-Interest-1-300x75.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/09131617\/Pipeline-Assessment-Around-Clients-Area-of-Interest-1-768x192.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/09131617\/Pipeline-Assessment-Around-Clients-Area-of-Interest-1-1536x384.jpg 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/09131617\/Pipeline-Assessment-Around-Clients-Area-of-Interest-1-1568x392.jpg 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/09131617\/Pipeline-Assessment-Around-Clients-Area-of-Interest-1.jpg 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-frequently-asked-questions\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1638968296058\"><strong class=\"schema-faq-question\"><strong>What are the most commonly prescribed drugs for Osteoporosis?<\/strong><\/strong> <p class=\"schema-faq-answer\">Bisphosphonates are the most commonly prescribed Osteoporosis drugs which include Alendronate (Fosamax, Binosto), Risedronate (Actonel, Atelvia), Ibandronate (Boniva) and Zoledronic acid (Reclast, Zometa).<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1638968331358\"><strong class=\"schema-faq-question\"><strong>What are the side effects of taking medications for Osteoporosis?<\/strong><\/strong> <p class=\"schema-faq-answer\">Some of the side effects for all the bisphosphonates include bone, muscle or joint pain. Other side effects may include nausea, heartburn, difficulty in swallowing, irritation of the oesophagus, and gastric ulcer.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1638968357063\"><strong class=\"schema-faq-question\"><strong>What is Osteoporosis life expectancy?<\/strong><\/strong> <p class=\"schema-faq-answer\">The life expectancy of Osteoporosis patients is in excess of around 15 years in both women and men but younger than 75 years and\u00a0 60 years respectively.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Osteoporosis can be characterized by a decrease in the density of bone, resulting in fragile bones which can decrease its strength. Osteoporosis leads to an extent of abnormally porous bones that are observed to be very compressible, just like a sponge. This skeleton disorder cripples the bones and consequently result in frequent fractures (breaks) in [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":14714,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[1500,3278,3277,3280],"industry":[17225],"therapeutic_areas":[],"class_list":["post-14685","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-osteoporosis","tag-osteoporosis-market","tag-osteoporosis-therapy","tag-osteoporosis-treatment","industry-pharmaceutical"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Osteoporosis Emerging Drugs Anticipated to Alter the Treatment Outcome<\/title>\n<meta name=\"description\" content=\"Novel therapies in the Osteoporosis domain by Teva Pharma, Haoma Medica, Enteris, others are expected to change the market&#039;s trajectory\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Osteoporosis Emerging Drugs Anticipated to Alter the Treatment Outcome\" \/>\n<meta property=\"og:description\" content=\"Novel therapies in the Osteoporosis domain by Teva Pharma, Haoma Medica, Enteris, others are expected to change the market&#039;s trajectory\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-12-08T14:13:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-12-17T04:49:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/08194458\/Novel-and-Upcoming-Osteoporosis-Drugs-Anticipated-to-Change-the-Markets-Trajectory-772-x-482-px.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Osteoporosis Emerging Drugs Anticipated to Alter the Treatment Outcome","description":"Novel therapies in the Osteoporosis domain by Teva Pharma, Haoma Medica, Enteris, others are expected to change the market's trajectory","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs","og_locale":"en_US","og_type":"article","og_title":"Osteoporosis Emerging Drugs Anticipated to Alter the Treatment Outcome","og_description":"Novel therapies in the Osteoporosis domain by Teva Pharma, Haoma Medica, Enteris, others are expected to change the market's trajectory","og_url":"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-12-08T14:13:07+00:00","article_modified_time":"2021-12-17T04:49:07+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/08194458\/Novel-and-Upcoming-Osteoporosis-Drugs-Anticipated-to-Change-the-Markets-Trajectory-772-x-482-px.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs","url":"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs","name":"Osteoporosis Emerging Drugs Anticipated to Alter the Treatment Outcome","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/08194458\/Novel-and-Upcoming-Osteoporosis-Drugs-Anticipated-to-Change-the-Markets-Trajectory-772-x-482-px.png","datePublished":"2021-12-08T14:13:07+00:00","dateModified":"2021-12-17T04:49:07+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Novel therapies in the Osteoporosis domain by Teva Pharma, Haoma Medica, Enteris, others are expected to change the market's trajectory","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs#faq-question-1638968296058"},{"@id":"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs#faq-question-1638968331358"},{"@id":"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs#faq-question-1638968357063"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/08194458\/Novel-and-Upcoming-Osteoporosis-Drugs-Anticipated-to-Change-the-Markets-Trajectory-772-x-482-px.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/08194458\/Novel-and-Upcoming-Osteoporosis-Drugs-Anticipated-to-Change-the-Markets-Trajectory-772-x-482-px.png","width":772,"height":482,"caption":"Novel-Upcoming-Osteoporosis-Drugs-Market"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs#faq-question-1638968296058","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs#faq-question-1638968296058","name":"What are the most commonly prescribed drugs for Osteoporosis?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Bisphosphonates are the most commonly prescribed Osteoporosis drugs which include Alendronate (Fosamax, Binosto), Risedronate (Actonel, Atelvia), Ibandronate (Boniva) and Zoledronic acid (Reclast, Zometa).","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs#faq-question-1638968331358","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs#faq-question-1638968331358","name":"What are the side effects of taking medications for Osteoporosis?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Some of the side effects for all the bisphosphonates include bone, muscle or joint pain. Other side effects may include nausea, heartburn, difficulty in swallowing, irritation of the oesophagus, and gastric ulcer.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs#faq-question-1638968357063","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/osteoporosis-emerging-drugs#faq-question-1638968357063","name":"What is Osteoporosis life expectancy?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The life expectancy of Osteoporosis patients is in excess of around 15 years in both women and men but younger than 75 years and\u00a0 60 years respectively.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/08194458\/Novel-and-Upcoming-Osteoporosis-Drugs-Anticipated-to-Change-the-Markets-Trajectory-772-x-482-px-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Osteoporosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Osteoporosis market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Osteoporosis Therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Osteoporosis treatment<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Osteoporosis<\/span>","<span class=\"advgb-post-tax-term\">Osteoporosis market<\/span>","<span class=\"advgb-post-tax-term\">Osteoporosis Therapy<\/span>","<span class=\"advgb-post-tax-term\">Osteoporosis treatment<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Dec 8, 2021","modified":"Updated on Dec 17, 2021"},"absolute_dates_time":{"created":"Posted on Dec 8, 2021 7:43 pm","modified":"Updated on Dec 17, 2021 10:19 am"},"featured_img_caption":"Novel-Upcoming-Osteoporosis-Drugs-Market","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/14685","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=14685"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/14685\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/14714"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=14685"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=14685"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=14685"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=14685"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=14685"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}